MIST Milestone Pharmaceuticals Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: MIST

Price (delayed)

$1.68

Market cap

$89.29M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.39

Enterprise value

$127.31M

Milestone Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of etripamil, a Phase 3 clinical-stage program, for the treatment of cardiovascular indications. Milestone Pharmaceuticals operates in Canada ...

Highlights
Milestone Pharmaceuticals's revenue has shrunk by 80% YoY and by 78% QoQ
The gross profit has dropped by 80% year-on-year and by 78% since the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://www.milestonepharma.com
Peers: OMER OMGA

Key stats

What are the main financial stats of MIST
Market
Shares outstanding
53.15M
Market cap
$89.29M
Enterprise value
$127.31M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
3.35
Price to sales (P/S)
72.17
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
127.31
Earnings
Revenue
$1M
EBIT
-$57.13M
EBITDA
-$57.04M
Free cash flow
-$46.54M
Per share
EPS
-$1.39
Free cash flow per share
-$1.08
Book value per share
$0.5
Revenue per share
$0.02
TBVPS
$1.75
Balance sheet
Total assets
$75.23M
Total liabilities
$58.46M
Debt
$51.78M
Equity
$16.77M
Working capital
$65.81M
Liquidity
Debt to equity
3.09
Current ratio
10.11
Quick ratio
9.58
Net debt/EBITDA
-0.67
Margins
EBITDA margin
-5,703.9%
Gross margin
100%
Net margin
-5,968.5%
Operating margin
-6,109.8%
Efficiency
Return on assets
-64.4%
Return on equity
-171%
Return on invested capital
-55.3%
Return on capital employed
-84%
Return on sales
-5,713.1%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

MIST stock price

How has the Milestone Pharmaceuticals stock price performed over time
Intraday
1.2%
1 week
9.09%
1 month
-4.55%
1 year
-53.33%
YTD
0.6%
QTD
-6.15%

Financial performance

How have Milestone Pharmaceuticals's revenue and profit performed over time
Revenue
$1M
Gross profit
$1M
Operating income
-$61.1M
Net income
-$59.69M
Gross margin
100%
Net margin
-5,968.5%
Milestone Pharmaceuticals's revenue has shrunk by 80% YoY and by 78% QoQ
The gross profit has dropped by 80% year-on-year and by 78% since the previous quarter
The operating income has contracted by 2.4% YoY
The net income fell by 2.2% YoY

Growth

What is Milestone Pharmaceuticals's growth rate over time

Valuation

What is Milestone Pharmaceuticals stock price valuation
P/E
N/A
P/B
3.35
P/S
72.17
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
127.31
The company's equity has shrunk by 75% YoY and by 41% QoQ
The P/B is 43% higher than the 5-year quarterly average of 2.3 and 13% higher than the last 4 quarters average of 2.9
MIST's P/S is 89% above its last 4 quarters average of 37.5
Milestone Pharmaceuticals's revenue has shrunk by 80% YoY and by 78% QoQ

Efficiency

How efficient is Milestone Pharmaceuticals business performance
Milestone Pharmaceuticals's return on equity has shrunk by 142% YoY and by 36% QoQ
The ROIC has soared by 66% YoY and by 11% QoQ

Dividends

What is MIST's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for MIST.

Financial health

How did Milestone Pharmaceuticals financials performed over time
The total assets is 29% greater than the total liabilities
The total assets has declined by 14% since the previous quarter
The current ratio has contracted by 14% YoY and by 3.3% from the previous quarter
The company's equity has shrunk by 75% YoY and by 41% QoQ
MIST's debt to equity has surged by 73% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.